Delaware Hemp THC Regulation: Laws, Bills & Compliance Guide

Executive Summary

Delaware lawmakers are navigating competing legislative proposals to regulate hemp-derived THC products in 2026, creating a critical juncture for the state's cannabis policy framework. The legislative debate centers on how to control intoxicating hemp products—such as delta-8 THC, delta-10 THC, and THCA—that have proliferated in retail stores following the 2018 Farm Bill's federal legalization of hemp. Delaware faces the challenge of balancing consumer safety, regulated cannabis market integrity, and hemp industry viability while multiple bills with different regulatory approaches move through the General Assembly. The outcome will determine whether Delaware adopts strict controls similar to neighboring states or creates a more permissive framework that allows hemp-derived intoxicants to coexist with the state's licensed cannabis market. This regulatory decision affects approximately 200 licensed cannabis operators, hundreds of hemp retailers, and thousands of Delaware consumers who currently purchase these products without age verification or potency limits.

Why This Matters

Delaware's hemp THC regulation directly impacts patient access, market competition, tax revenue, and public health across a state of nearly one million residents. The regulatory outcome affects multiple stakeholder groups with competing interests. Licensed cannabis dispensaries in Delaware argue that unregulated hemp products undercut their heavily taxed and tested inventory, creating unfair competition. These operators invested millions in licensing fees and compliance infrastructure under Delaware's medical marijuana program, established in 2011, and the adult-use market that launched in 2023. Hemp retailers counter that their products are federally legal and serve consumers seeking milder effects or lower prices than dispensary cannabis. Public health officials express concern about unregulated delta-8 THC and THCA products reaching minors through convenience stores and gas stations without age verification. The Delaware Division of Public Health reported increased calls to poison control regarding hemp-derived intoxicants in 2025, though specific numbers remain unpublished. Parents and educators have raised alarms about colorful packaging and candy-like edibles marketed near schools. From a fiscal perspective, Delaware collected approximately $15 million in cannabis excise taxes in 2025 from licensed dispensaries. Unregulated hemp sales—estimated at $8-12 million annually by industry observers—generate only standard sales tax revenue. The state's budget office has not released official projections on potential revenue from regulated hemp products. The Delaware Cannabis Control Act, which governs adult-use sales, does not address hemp-derived intoxicants. This regulatory gap has allowed products containing delta-8 THC, delta-9 THC derived from hemp, delta-10 THC, THC-O, and THCA flower to enter retail channels without testing, labeling standards, or purchase limits. Consumer advocacy groups argue that without regulation, purchasers cannot verify product safety or accurate potency claims.

Background and History

Delaware's current hemp THC dilemma stems from the intersection of federal hemp legalization, state cannabis policy evolution, and the chemistry of cannabinoid conversion.

The 2018 Farm Bill Foundation

The Agricultural Improvement Act of 2018, commonly called the 2018 Farm Bill, removed hemp from Schedule I of the Controlled Substances Act. The legislation defined hemp as Cannabis sativa L. with delta-9 THC concentration not exceeding 0.3 percent on a dry weight basis. This federal change, signed into law on December 20, 2018, legalized hemp cultivation and commerce nationwide. Delaware responded by enacting the Delaware Hemp Program in 2019 under 3 Del. C. § 901 et seq. The state Department of Agriculture received USDA approval for its hemp plan in February 2020, allowing licensed farmers to grow hemp for fiber, grain, and cannabinoid extraction. By 2025, Delaware had approximately 45 licensed hemp growers cultivating roughly 800 acres.

The Rise of Intoxicating Hemp Products

The 2018 Farm Bill's focus on delta-9 THC concentration created an unintended loophole. Manufacturers discovered they could produce intoxicating cannabinoids from CBD through chemical conversion or selective breeding. Delta-8 THC, an isomer of delta-9 THC, emerged in retail markets nationwide by 2020, marketed as "legal THC" or "diet weed." Delta-8 THC occurs naturally in cannabis in trace amounts but can be synthesized from CBD through chemical processes involving acids and heat. The resulting compound produces intoxicating effects similar to delta-9 THC, though users typically report milder psychoactive experiences. Because the final product derives from legal hemp and the delta-9 THC content remains below 0.3 percent, manufacturers argued it fell within the Farm Bill's definition. By 2021, delta-8 products appeared in Delaware convenience stores, smoke shops, and dedicated hemp retailers. Products included vape cartridges, gummies, tinctures, and flower sprayed with delta-8 distillate. No state agency regulated these products for safety, potency, or age-restricted sales.

Delaware's Cannabis Legalization Timeline

Delaware established its medical marijuana program through the Delaware Medical Marijuana Act in 2011, signed by Governor Jack Markell. The program authorized licensed compassion centers to dispense cannabis to qualified patients with debilitating conditions. The first dispensary opened in 2015 after regulatory delays. Adult-use legalization followed a more circuitous path. In April 2023, the Delaware General Assembly passed House Bill 1 and House Bill 2 without Governor John Carney's signature, allowing them to become law automatically. House Bill 1 legalized possession of up to one ounce of cannabis for adults 21 and older. House Bill 2 created the regulatory framework for licensed cultivation, manufacturing, testing, and retail sales. The Delaware Division of Alcohol and Tobacco Enforcement, renamed the Office of the Marijuana Commissioner, began accepting license applications in October 2023. The first adult-use dispensaries opened in March 2024, with existing medical operators receiving priority licensing. By May 2026, Delaware had 22 licensed adult-use retailers, 8 cultivation facilities, and 4 testing laboratories.

The Regulatory Gap Emerges

Delaware's cannabis laws focused on traditional marijuana products containing delta-9 THC. The statutes did not address hemp-derived cannabinoids or products that technically met the federal hemp definition while producing intoxicating effects. This created a two-tier market: heavily regulated dispensary cannabis subject to testing, taxation, and strict oversight, and unregulated hemp products sold without quality controls. The situation intensified in 2024 and 2025 as manufacturers introduced additional hemp-derived intoxicants. Delta-10 THC, another THC isomer, appeared in vape products. THC-O acetate, a synthetic cannabinoid, briefly entered the market before the DEA issued guidance in February 2023 stating that THC-O did not meet the Farm Bill's definition because it does not occur naturally in the cannabis plant. Most significantly, THCA flower emerged as a major product category in 2024. THCA (tetrahydrocannabinolic acid) is the non-intoxicating precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaping, THCA converts to delta-9 THC through decarboxylation. Growers discovered they could cultivate cannabis plants that tested below 0.3 percent delta-9 THC while containing high THCA levels—sometimes exceeding 20 percent. Because federal and state hemp definitions measured only delta-9 THC, not total THC or THCA, these products technically qualified as legal hemp despite producing effects indistinguishable from marijuana. Delaware hemp retailers began selling THCA flower in late 2024, marketing it as "legal weed" and "hemp flower." The products looked, smelled, and functioned identically to cannabis sold in licensed dispensaries but cost significantly less due to the absence of excise taxes and regulatory compliance expenses.

Other States' Responses

Delaware's hemp THC dilemma mirrors challenges faced nationwide. By May 2026, at least 22 states had enacted laws restricting or banning intoxicating hemp products. Approaches varied widely. Colorado adopted comprehensive regulations in 2023 requiring hemp-derived intoxicants to be sold only through licensed marijuana dispensaries, effectively treating them as cannabis products. Oregon took a similar approach, banning delta-8 THC and requiring all intoxicating hemp products to enter the regulated cannabis supply chain. North Carolina banned delta-8 THC and other synthetic cannabinoids in 2022 but allowed hemp-derived delta-9 THC products under strict labeling and potency limits. Minnesota created a separate regulatory framework for hemp-derived edibles in 2022, capping THC content at 5 milligrams per serving and 50 milligrams per package. Several states, including Kentucky and South Carolina, banned all intoxicating hemp products outright. Others, such as California and Michigan, struggled to enforce existing bans as products continued appearing in retail stores. The regulatory patchwork created confusion for consumers and businesses operating across state lines. National hemp trade associations advocated for federal clarity, while cannabis industry groups pushed for state-level restrictions to protect licensed markets.

Key Players

Delaware General Assembly

The Delaware General Assembly holds primary authority over cannabis and hemp policy through its legislative power. The 151st General Assembly, seated in January 2025, includes several members who championed adult-use legalization and others who opposed it. Key legislators involved in hemp THC regulation include members of the House and Senate Health and Human Services committees, which typically handle cannabis-related bills. Representative Edward Osienski, a longtime advocate for cannabis reform, has been involved in previous marijuana legislation. Senator Trey Paradee played a central role in adult-use legalization efforts. The specific sponsors and content of the competing hemp regulation bills introduced in 2026 have not been fully disclosed in available public records.

Office of the Marijuana Commissioner

The Office of the Marijuana Commissioner, operating within the Delaware Department of Safety and Homeland Security, oversees the state's cannabis licensing and compliance. Commissioner Rob Coupe, appointed in 2023, manages the regulatory framework for cultivation, manufacturing, testing, and retail operations. The office lacks explicit authority over hemp-derived products under current statutes, creating jurisdictional ambiguity.

Delaware Department of Agriculture

The Delaware Department of Agriculture administers the state's hemp program under USDA oversight. The department licenses hemp growers and processors but does not regulate retail hemp products or their cannabinoid content beyond ensuring compliance with the 0.3 percent delta-9 THC threshold. Secretary Michael Scuse has not publicly commented on intoxicating hemp products.

Licensed Cannabis Operators

Delaware's licensed cannabis dispensaries, cultivation facilities, and manufacturers have a direct financial interest in hemp regulation. These operators argue that unregulated hemp products create unfair competition by avoiding the costs of licensing, testing, security, and taxation. First State Compassion Center, one of Delaware's original medical marijuana dispensaries, has advocated for bringing hemp-derived intoxicants under the same regulatory framework as cannabis.

Hemp Industry Stakeholders

Hemp farmers, processors, and retailers oppose restrictions that would eliminate their market for cannabinoid products. National organizations such as the U.S. Hemp Roundtable have argued that hemp-derived products are federally legal and should not be conflated with marijuana. Delaware-based hemp retailers contend that their products serve consumers who prefer lower-potency options or cannot afford dispensary prices.

Public Health and Safety Advocates

The Delaware Division of Public Health, medical professionals, and substance abuse prevention organizations have raised concerns about unregulated intoxicating products. The Delaware chapter of the American Academy of Pediatrics has advocated for age restrictions and child-resistant packaging. Nemours Children's Health has expressed concern about accidental pediatric ingestion of hemp-derived edibles.

Legal and Regulatory Framework

Delaware's hemp THC regulatory challenge exists at the intersection of federal drug scheduling, state cannabis statutes, and agricultural hemp law.

Federal Framework

The Controlled Substances Act, 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I substance. The 2018 Farm Bill amended the CSA to exclude hemp, defined as cannabis with delta-9 THC concentration not exceeding 0.3 percent on a dry weight basis. This definition appears in 7 U.S.C. § 1639o. The DEA has maintained that delta-8 THC and other synthetically derived cannabinoids remain Schedule I controlled substances. In a May 2022 letter to the Alabama Board of Pharmacy, the DEA stated that "delta-8 THC synthesized from non-cannabis materials" does not meet the Farm Bill's hemp definition. However, the agency has not issued comprehensive regulations addressing all hemp-derived intoxicants, creating ongoing legal ambiguity. The FDA has asserted authority over hemp-derived products containing CBD and other cannabinoids under the Federal Food, Drug, and Cosmetic Act. The agency has issued warning letters to companies making unsubstantiated health claims but has not established a comprehensive regulatory framework for hemp-derived intoxicants sold for recreational use.

Delaware Cannabis Law

Delaware's adult-use cannabis framework rests on two statutes. 16 Del. C. § 4701 et seq., enacted through House Bill 1, legalized possession and home cultivation. 4 Del. C. § 901 et seq., enacted through House Bill 2, created the licensing and regulatory structure. The statutes define "marijuana" as "all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin." This definition includes an exception for "the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of germination." Critically, the statutes do not explicitly address hemp as defined by federal law or hemp-derived cannabinoids. This omission created the regulatory gap that allows intoxicating hemp products to operate outside the licensed cannabis framework.

Delaware Hemp Law

Delaware's hemp program, codified at 3 Del. C. § 901 et seq., authorizes the Department of Agriculture to license hemp cultivation and processing. The statute adopts the federal definition of hemp as cannabis with delta-9 THC concentration not exceeding 0.3 percent. The law focuses on agricultural production and does not establish retail regulations, testing requirements, or age restrictions for hemp-derived products.

Potential Regulatory Approaches

States addressing intoxicating hemp products have employed several regulatory models: **Total prohibition**: Banning all hemp-derived intoxicants by defining them as controlled substances under state law, regardless of federal hemp status. **Integration into cannabis framework**: Requiring hemp-derived intoxicants to be sold only through licensed cannabis dispensaries, subject to the same testing, taxation, and oversight. **Separate hemp regulation**: Creating a distinct regulatory framework for hemp-derived products with specific potency limits, labeling requirements, and age restrictions, but allowing sales outside licensed dispensaries. **Potency-based thresholds**: Permitting hemp products below specified THC concentrations (e.g., 5 mg per serving) while prohibiting higher-potency items. **THCA measurement**: Redefining hemp to include total THC (delta-9 THC plus THCA) rather than delta-9 THC alone, effectively banning high-THCA flower. Delaware lawmakers must choose among these approaches or craft a hybrid model addressing the state's specific market conditions and policy priorities.

The Competing Bills

Multiple legislative proposals introduced in the Delaware General Assembly in 2026 reflect divergent approaches to hemp THC regulation, though specific bill text and sponsor details remain limited in public reporting. According to available information, at least two distinct bills are under consideration, representing different regulatory philosophies. One approach would bring hemp-derived intoxicants under the existing cannabis regulatory framework, requiring these products to be sold through licensed dispensaries with the same testing, labeling, and taxation requirements as marijuana. This model aligns with approaches adopted in Colorado and Oregon. A competing proposal would create a separate regulatory tier for hemp products, establishing potency limits, age restrictions, and labeling requirements while allowing sales to continue outside licensed dispensaries. This approach would likely involve the Department of Agriculture or a newly designated agency overseeing hemp retail compliance. The bills reportedly differ on several key provisions: **Potency limits**: Whether to cap THC content per serving and per package, and at what levels. **Sales channels**: Whether hemp-derived intoxicants must be sold through licensed cannabis dispensaries or can be sold in general retail stores with appropriate licensing. **Testing requirements**: Whether hemp products must undergo laboratory testing for potency, pesticides, heavy metals, and microbial contaminants comparable to cannabis testing standards. **Taxation**: Whether to apply the cannabis excise tax to hemp products or impose a different tax structure. **THCA treatment**: Whether to redefine hemp to include total THC, effectively prohibiting high-THCA flower. **Existing inventory**: How to handle hemp products already in retail channels, including potential grandfather provisions or mandatory removal. **Licensing and fees**: What licenses would be required for hemp retailers and at what cost. The legislative process involves committee hearings, stakeholder testimony, and potential amendments before floor votes. The timing of final passage remains uncertain, with some observers predicting action before the General Assembly's summer recess while others expect the issue to extend into the fall session.

Market and Business Implications

Delaware's regulatory decision will reshape a multi-million dollar market segment and determine competitive dynamics between licensed cannabis operators and hemp retailers.

Licensed Cannabis Market Impact

Delaware's licensed cannabis dispensaries generated approximately $85 million in gross sales in 2025, according to industry estimates. The state collected roughly $15 million in excise taxes at a 15 percent rate on adult-use sales. Medical marijuana sales, which are not subject to excise tax, added approximately $12 million. Licensed operators argue that unregulated hemp competition has suppressed their sales growth. Dispensary cannabis typically costs $35-60 per eighth ounce for flower and $25-50 for edible products. Hemp-derived THCA flower retails for $15-30 per eighth ounce, while delta-8 gummies cost $10-20 per package. The price differential reflects the absence of excise taxes, testing costs, and regulatory compliance expenses in the hemp market. If Delaware integrates hemp products into the licensed cannabis framework, dispensaries would gain access to lower-priced product lines, potentially attracting price-sensitive consumers. However, the added regulatory costs would likely increase hemp product prices, reducing the competitive advantage. Some smaller hemp retailers might exit the market rather than pursue cannabis licenses, which require substantial capital investment and compliance infrastructure.

Hemp Industry Disruption

Delaware's hemp retail sector includes an estimated 75-100 stores selling cannabinoid products, ranging from dedicated hemp shops to convenience stores and gas stations. These businesses employ approximately 300-400 workers. Total hemp-derived intoxicant sales in Delaware likely reached $8-12 million in 2025, though no official data exists. Strict regulation or prohibition would force these retailers to either obtain cannabis licenses, cease cannabinoid sales, or operate illegally. The capital requirements for cannabis licensing—including application fees, security systems, inventory tracking, and testing protocols—would be prohibitive for many small operators. Industry observers predict that 50-70 percent of current hemp retailers would exit the cannabinoid market under a dispensary-only model. Hemp farmers and processors face different impacts. If regulations focus on retail sales channels rather than banning production, farmers could continue cultivating hemp for CBD, fiber, and grain markets. However, the loss of the intoxicating cannabinoid market would reduce demand for high-cannabinoid hemp varieties. Delaware's hemp cultivation sector remains relatively small, with most biomass exported to out-of-state processors.

Consumer Access and Pricing

Delaware consumers currently access intoxicating hemp products through numerous retail channels without purchase limits or age verification. Regulation would likely reduce access points, increase prices, and impose age restrictions. These changes would affect different consumer segments variably. Price-sensitive consumers who currently purchase hemp products due to lower costs might shift to illicit markets if prices rise substantially. Consumers seeking mild effects might find fewer options if low-potency products become economically unviable under full cannabis regulation. Conversely, consumers prioritizing product safety and quality assurance would benefit from mandatory testing and labeling standards. Geographic access could change significantly. Delaware's 22 licensed dispensaries concentrate in more populous areas, while hemp products currently sell in rural convenience stores and gas stations. A dispensary-only model would reduce access in rural communities, potentially increasing travel distances for consumers.

Tax Revenue Projections

If Delaware applies its 15 percent cannabis excise tax to hemp-derived intoxicants, the state could generate an additional $1.2-1.8 million annually based on current sales estimates. However, this projection assumes sales volumes remain constant despite price increases and reduced retail access. More realistic estimates accounting for market contraction suggest $800,000-1.2 million in new annual revenue. A separate hemp tax at a lower rate might preserve more market activity while generating revenue. A 5 percent excise tax on hemp products could yield $400,000-600,000 annually with less market disruption. These figures remain modest compared to Delaware's overall cannabis tax revenue and state budget, but they represent meaningful funding for public health, substance abuse prevention, or regulatory enforcement programs.

What Experts Say

Policy analysts, industry representatives, and public health officials have articulated divergent positions on how Delaware should regulate hemp-derived intoxicants. Cannabis industry advocates argue that allowing unregulated hemp products undermines the policy rationale for cannabis legalization. According to this view, Delaware created a licensed, taxed, and tested cannabis market to ensure consumer safety and generate public revenue. Permitting functionally identical products to bypass this framework contradicts those goals. Representatives of licensed operators contend that hemp-derived intoxicants should face the same regulatory requirements as marijuana to ensure competitive equity and consumer protection. Hemp industry representatives counter that their products are federally legal and serve consumers seeking alternatives to higher-potency cannabis. They argue that hemp-derived cannabinoids offer milder effects suitable for consumers who find dispensary cannabis too strong. Hemp advocates also emphasize that many hemp retailers are small businesses that cannot afford cannabis licensing costs. They propose a middle-ground approach with age restrictions, labeling requirements, and potency limits that preserve market access while addressing safety concerns. Public health experts focus on the absence of quality controls in the current hemp market. Toxicologists note that unregulated delta-8 THC products may contain residual solvents, heavy metals, or other contaminants from the chemical conversion process. The lack of mandatory testing means consumers cannot verify potency claims or identify potentially harmful adulterants. Pediatricians emphasize the risk of accidental child ingestion when intoxicating edibles are sold without child-resistant packaging or age verification. Legal scholars observe that the regulatory gap stems from the 2018 Farm Bill's focus on delta-9 THC concentration without considering total intoxicating potential. Some argue that Congress did not intend to legalize intoxicating hemp products and that the current situation represents an unintended loophole. Others contend that the statutory language is clear and that hemp-derived cannabinoids meeting the 0.3 percent threshold are lawful under federal law, regardless of intoxicating effects. Economic analysts note that Delaware's decision will influence neighboring states' approaches. If Delaware adopts permissive hemp regulations while Maryland and Pennsylvania impose restrictions, cross-border shopping could increase. Conversely, if Delaware bans hemp-derived intoxicants while surrounding states allow them, Delaware retailers might lose sales to out-of-state competitors. Consumer advocates emphasize the need for clear labeling, accurate potency information, and consistent dosing. They argue that current hemp products often lack reliable information about cannabinoid content, making it difficult for consumers to use them safely and predictably. Mandatory testing and standardized labeling would address these concerns regardless of whether products are sold through dispensaries or general retail channels.

What's Next

Delaware's hemp THC regulatory framework will likely take shape through legislative action in 2026, with implementation extending into 2027. The immediate timeline depends on the General Assembly's legislative calendar. The Delaware General Assembly typically conducts most substantive business between January and June, with a summer recess beginning in late June or early July. If lawmakers prioritize hemp regulation, final passage could occur before the summer break. However, if competing bills remain unreconciled or stakeholder opposition intensifies, the issue might carry over to the fall session or even the 2027 legislative year. Committee hearings will provide opportunities for stakeholder testimony and public input. Licensed cannabis operators, hemp retailers, public health officials, and consumer advocates will likely present competing perspectives. These hearings may reveal consensus on certain provisions—such as age restrictions and child-resistant packaging—while highlighting irreconcilable differences on issues like sales channels and potency limits. If legislation passes, implementation will require regulatory rulemaking. The responsible agency—whether the Office of the Marijuana Commissioner, the Department of Agriculture, or another entity—must develop detailed regulations addressing licensing procedures, testing protocols, labeling requirements, and enforcement mechanisms. This rulemaking process typically takes 6-12 months and includes public comment periods. Several scenarios could unfold: **Comprehensive integration**: Delaware brings all hemp-derived intoxicants under the cannabis regulatory framework, requiring dispensary-only sales. Existing hemp retailers either obtain cannabis licenses or exit the market. Implementation occurs in phases, with a transition period for existing inventory and license applications. **Tiered regulation**: Delaware creates separate regulatory tiers for different product categories. High-potency items like THCA flower require dispensary sales, while lower-potency products (e.g., 5 mg edibles) can be sold in general retail stores with appropriate licensing and age restrictions. **Prohibition**: Delaware bans all intoxicating hemp products, defining them as controlled substances under state law. Enforcement focuses on retail sales, with penalties for non-compliant businesses. **Status quo**: Competing bills fail to advance, leaving the regulatory gap unresolved. Hemp products continue selling without oversight, and the issue returns in future legislative sessions. The outcome will influence other states grappling with similar challenges. Delaware's approach could serve as a model for neighboring jurisdictions or as a cautionary example, depending on implementation success and unintended consequences. Stakeholders should monitor several key dates and developments: - Delaware General Assembly committee hearings on hemp regulation bills (dates to be announced) - Floor votes in the House and Senate (likely May-June 2026 if bills advance) - Governor's signature or veto decision (within 10 days of passage) - Regulatory rulemaking proceedings (6-12 months post-enactment) - License application periods for hemp retailers seeking cannabis licenses (if applicable) - Effective dates for new restrictions or requirements (typically 90-180 days after enactment) Industry participants should prepare for multiple scenarios by evaluating compliance costs, license application requirements, and business model adjustments. Consumers should anticipate potential changes in product availability, pricing, and retail access.

Further Reading

• Delaware Cannabis Control Act, 4 Del. C. § 901 et seq. - https://delcode.delaware.gov/title4/c009/
• Delaware Hemp Program, 3 Del. C. § 901 et seq. - https://delcode.delaware.gov/title3/c009/
• Agricultural Improvement Act of 2018 (Farm Bill), Pub. L. 115-334 - https://www.congress.gov/bill/115th-congress/house-bill/2
• Delaware Office of the Marijuana Commissioner - https://marijuana.delaware.gov/
• Delaware Department of Agriculture Hemp Program - https://agriculture.delaware.gov/hemp/
• DEA Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.deadiversion.usdoj.gov/21cfr/21usc/
• USDA Hemp Production Program - https://www.ams.usda.gov/rules-regulations/hemp
• FDA Regulation of Cannabis and Cannabis-Derived Products - https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• National Conference of State Legislatures: State Hemp and CBD Laws - https://www.ncsl.org/agriculture-and-rural-development/state-hemp-and-cbd-laws
• Marijuana Moment coverage of Delaware cannabis policy - https://www.marijuanamoment.net/tag/delaware/